ABSTRACT: According to the activity−structure relationship of the C-13 side chain in paclitaxel or docetaxel, eighteen novel paclitaxel−dehydroepiandrosterone (DHEA) hybrids were designed and synthesized by Pd(II)-catalyzed Suzuki−Miyaura cross-coupling of 17-trifluoromethanesulfonic enolate-DHEA with different aryl boronic acids. The in vitro anticancer activity of the hybrids against a human liver cancer cell line (HepG-2) was evaluated by MTT assay, showing that most of these hybrids possessed moderate antiproliferative activity against the HepG-2 cancer cell line. Among these hybrids, three ones (7b, 7g, and 7i) with ortho-substituents in the phenyl group of the D-ring of DHEA analogues exhibited moderate anticancer activity. The optimal compound 7i showed superior anticancer activity against the HepG-2 cell line with an IC 50 value of 26.39 μM.
■ INTRODUCTION
Paclitaxel (Taxol), isolated from the bark of Taxus brevifolia Nutt in the late 1960s, 1 and its semisynthetic derivatives docetaxel (Taxotere) and cabazitaxel (Jevana) (Figure 1) currently serve as the most widely used clinical antitumor drugs against breast cancer, ovarian cancer, non-small cell lung cancer, and prostate cancer, among various chemotherapeutic agents. 2 They are known to exert their therapeutic effect by their ability to accelerate the polymerization of tubulin and stabilize the resultant microtubules, which leads to apoptosis through a cell-signaling cascade. 3−5 Because the significant role of taxoids in the field of anticancer and their undesirable side effects as well as drug resistance, numerous endeavors has been devoted to in-depth research on the structure−activity relationships (SARs) of paclitaxel to reveal the minimal structural requirements essential for biological activity and develop next-generation taxoid anticancer agents with better pharmacological properties and improved activity. 2, 6, 7 As a result of the SAR studies, the oxetane D-ring and unique C-13 side chains of paclitaxel were indispensable active groups, 8−12 and it has been justified by a range of successful studies of paclitaxel mimics that the complex taxane skeleton was replaced by a structurally simplified core but retained part of the three-dimensional configuration and phenylisoserine side chain of paclitaxel. 13−17 Currently, a good deal of bioactive taxoid mimics have resulted from modifications of the functional groups on the taxane baccatin core or modification of the size of the carbon rings contained within the molecule. 2 By contrast, less attention has been paid to the hybridization of paclitaxel with other biologically active natural products. In 2000, Wandless et al. 18 reported six paclitaxel−daunorubicin hybrids, and all of them displayed cytotoxic activity, although less than the parent monomers. In 2005, Gueńard et al. 16 reported eight paclitaxel-steroidal hybrids bearing the phenylisoserine side chain to mimic "T-form" docetaxel. Their cytotoxicity against the KB cell line and MCF-7 cell line was not as excellent as that of docetaxel and did not show any inhibitory activity for microtubule disassembly. Although the above studies did not render any taxoid mimic with improved anticancer activity, Figure 1 . Structures of paclitaxel, docetaxel, cabazitaxel, and abiraterone.
they revealed that paclitaxel−natural product-based hybrids were potential agents which could be possibly extended and strengthen the medical utility of Taxol. Furthermore, the highly complex structure of paclitaxel, especially its baccatin component, prevents the large-scale production of synthetic paclitaxel, which makes paclitaxel prohibitively expensive. Therefore, the combination of the minimal pharmacophore of the taxoid (the C-13 phenylisoserine side chain) with other accessible taxane skeleton-like natural compounds to generate a baccatin-free compound with a taxane-like conformation which retains appreciable antitumor activity is necessary and exciting.
In our previous studies, 8 assays for antiproliferative activity indicated that paclitaxel mimics possessing only C-13 side chains and oxetane D-ring structures showed moderate antitumor activities. This result encouraged us to explore other paclitaxel mimics with both C-13 side chains and widely distributed paclitaxel-like natural skeletons. Kingston et al. 19 synthesized twelve steroid-linked Taxol analogues as potential anticancer drugs. They revealed that all conjugates were cytotoxic to the A2870 ovarian cancer cell line, although less so than Taxol. Inspired by this, we envisioned searching for more steroid analogues as the substituents of the baccatin core of Taxol. Dehydroepiandrosterone (DHEA) is a steroidal hormone which aids in the prevention of cancer in rodents. Studies show that low circulating levels of DHEA have been associated with a higher incidence of breast cancer in women. 20 In addition to its economical and accessible properties, the conformation and structure of DHEA are similar to those of taxane. Most important of all, abiraterone (Figure 1 ), formed by introducing a nitrogen heterocyclic ring into the D-ring of DHEA, has been used to treat cancer in clinic. 21 There may be potential advantages for hybrid molecules if both drugs can be deactivated as the result of linking function and then released together. 18 Accordingly, all the abovementioned benefits encourage us to synthesize paclitaxel−DHEA mimic hybrids to extend and strengthen the therapeutic use of paclitaxel for paclitaxel-resistant or paclitaxel-insensitive tumors. Herein, we reported the synthesis and in vitro anticancer activity of eighteen paclitaxel−DHEA hybrids, in which the intricate baccatin core is structurally replaced by DHEA analogues. In the synthesis strategy, the Suzuki−Miyaura reaction which is known for the formation of Csp 2 −Csp 2 bonds was used as a key step to introduce different aromatic chains in the D-ring of DHEA to increase the diversity of this natural product. It is worth mentioning that this reaction is mainly used in the total synthesis of natural products; 22−26 rare examples of direct modification of natural compounds with this reaction have been reported. 27, 28 DHEA hybrids. The DHEA analogues 4a−4q were subjected to esterification with the purchased oxazolidinecarboxylic acids 5a or 5b, 29 which resulted in the formation of oxazolidinecarboxylate 6a−6r (Scheme 1). Treatment of the intermediates 6a−6r with p-toluenesulfonic acid yielded eighteen paclitaxel−DHEA hybrids 7a−7r in 60−85% yields.
Biological Activity Evaluation. The eighteen newly synthesized hybrids were evaluated in vitro for their anticancer activity against a human tumor cell line (HepG-2) by MTT assay. The most interesting results are presented in Table 1 . All the hybrids showed less anticancer activity than the positive control Taxol. Three ones (7b, 7g, and 7i) with orthosubstituents in the phenyl group of the D-ring of DHEA analogues indicated moderate anticancer activity, better than that of the others. Specifically, compound 7i exhibited the best anticancer activity against cell line HepG-2 with an IC 50 value of 26.39 μM.
■ CONCLUSIONS
To summarize, eighteen novel paclitaxel−DHEA hybrids were designed and synthesized according to the SARs of Taxol and our previous studies, 8 using the Suzuki−Miyaura reaction as a key step to directly introduce different aromatic chains in the D-ring of DHEA. The MTT assay showed all the hybrids displayed less anticancer activity than the positive control Taxol. Three ones (7b, 7g, and 7i) with ortho-substituents in the phenyl group of the D-ring of DHEA analogues indicated moderate anticancer activity, better than that of the others. The results may give inspiration and guide the following modification of paclitaxel-like hybrids with improved anticancer activity. The use of a baccatin-free hybrid component might be an effective strategy to establish a paclitaxel-based hybrid library.
■ EXPERIMENTAL SECTION
Chemistry. Materials and General Method. Unless otherwise noted, the reagents are commercially available and used without further purification. Synthesized compounds were purified by chromatography on silica gel (200−300 mesh) purchased from Qingdao Haiyang Chemical Co., Ltd. NMR spectra were recorded on a Bruker AV 600 or 400 NMR spectrometer in CDCl 3 with tetramethylsilane as the internal standard; chemical shifts (δ) were reported in ppm values and J in Hz. HR-ESI-MS data were measured using a Q-TOF micro mass spectrometer (Waters).
Preparation of Compound 1. A solution of DHEA (10.4 mmol, 1.0 equiv), imidazole (31.2 mmol, 3.0 equiv), and 4-Ndimethylaminopyridine (1.04 mmol, 0.1 equiv) in dry dichloromethane (30 mL) was stirred at room temperature for 5 min. Then, tert-butyldimethylsilyl chloride (20.8 mmol, 2.0 equiv) was added to the mixed solution at 40°C and the resultant mixture was stirred at the same temperature for 2 h until thin-layer chromatography showed complete consumption of the starting compound. Then, the reaction mixture was extracted with water and ethyl acetate (EtOAc) three times. The organic phase was washed with brine water and dried over Na 2 SO 4 . After removal of the solvent, the residue was purified by silica gel column chromatography (EtOAc/petroleum ether, 1:10) to afford compound 1 as a white solid in 90% yield. The 1 H NMR data are consistent with the reported literature. 30 Preparation of Compound 2. KHMDS [0.5 M in tetrahydrofuran (THF), 3 mL, 1.5 mmol, 3.0 equiv] was added to the mixture of compound 1 (0.5 mmol, 1.0 equiv) and PhN(Tf) 2 (0.75 mmol, 1.5 equiv) in dry THF at −78°C and the resultant mixture was stirred at the same temperature for 2 h and then neutralized with saturated NH 4 Cl (aq.). The mixture was extracted with EtOAc three times. The organic phase was washed with water and brine and dried over Na 2 SO 4 . After removal of the solvent, the crude mixture was purified by silica gel column chromatography (EtOAc/ petroleum ether, 1:50) to afford the desired triflate 2 as a white solid, yield 65%. The 1 H NMR data are consistent with the reported literature. 31 General Procedure for the Compounds 3a−3q. A suspension of compound 2 (0.1 mmol, 1.0 equiv), boronic acid compound (0.1 mmol, 1 equiv), Na 2 CO 3 (0.125 mmol, 1.25 equiv) and PdCl 2 (PPh 3 ) 2 (0.003 mmol, 0.03 equiv) in toluene (2 mL), EtOH (0.4 mL), and water (1 mL) was stirred at 75°C under argon for 0.5 h. Then, the mixture was added to saturated NaHCO 3 aq. (5.0 mL) and extracted with excess EtOAc three times. The organic phase was washed with water and brine and dried over Na 2 SO 4 . The solvent was removed and the crude mixture was purified by silica gel column chromatography (EtOAc/petroleum ether, 1:20) to obtain the desired compounds 3a−3q as a white solid, yield 60−90%.
Compound 3a, yield 60 12 mmol, 1.2 equiv) , and 4-(dimethylamino) pyridine (0.1 mmol, 1.0 equiv) in toluene (5 mL) was stirred at 80°C for 18 h and then quenched with HCl (1 M). The mixture was added to a saturated solution of NaHCO 3 (aq.) to adjust the mixture to pH 7 and then the mixture was extracted with EtOAc three times. The organic layer was treated with aqueous HCl (1 M), a saturated solution of NaHCO 3 (aq.), and then brine, and each washing was performed at least three times. The organic layer was washed with 5% NaHCO 3 liquid (3 × 15 mL) and dried over Na 2 SO 4 . The residue was purified by silica gel column chromatography (EtOAc/petroleum ether, 1:15) to afford the corresponding compounds 6a−6r as a white solid, yield 46−88%.
Compound 6a, 02 (m, 3H), 1.94−1.37 (m, 11H), 1.10 (s, 3H,  overlapped), 1.09 (s, 3H, overlapped) . 13 C NMR (100 MHz, CDCl 3 ): δ 169.7, 160.0, 152.8, 148.4, 139.6, 139.0, 135.8,  132.7, 130.7, 130.4, 130.2, 129.1, 128.9, 128.8, 128.3, 128.1,  127.2 × 4, 122.9, 121.6, 121.4, 113.6, 75.8, 57.6, 55.4, 50.3 (m, 8H), 1.11 (s, 3H), 1.07 (s, 3H) 13 C NMR (100 MHz, CDCl 3 ): δ 169. 6, 165.6, 159.9, 159.7, 144.2, 139.5, 135.7, 132.4, 130.7, 130.1, 128.8, 128.7, 128.3, 128.1, 127.1, 122.9, 113.5, 112.4, 75.7, 56.7, 55.3, 50.5, 49.4, 38.0, 36.9, 36.9 × 2, 35.3, 32.2, 31.6, 30.8, 27.6, 20.8, 19.3, 16.4, 12. General Procedure for the Compounds 7a−7r. The ester compound 6 (0.05 mmol 1.0 equiv) was added to MeOH (2 mL) and treated with 4-toluene sulfonyl chloride (0.3 mmol, 6 .0 equiv). The reaction mixture was stirred at room temperature for 6 h and then diluted with EtOAc. The organic layer was washed with a saturated solution of NaHCO 3 (aq.) and brine, dried with Na 2 SO 4 , filtered, and concentrated. The crude mixture was purified by silica gel column chromatography (EtOAc/petroleum ether, 1:12) to afford the desired hybrids 7a−7r as a white solid, yield 60−85%.
Compound 7a, 
